Veradigm Inc. (MDRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veradigm Inc. (MDRX) has a cash flow conversion efficiency ratio of 0.024x as of September 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.14 Million) by net assets ($1.18 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MDRX net asset quality index to measure how much of total assets are equity-financed.
Veradigm Inc. - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Veradigm Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Veradigm Inc. to evaluate the quality of earnings relative to operating cash generation.
Veradigm Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veradigm Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dap Gayrimenkul Gelistirme AS
IS:DAPGM
|
0.016x |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
0.002x |
|
Innocean Worldwide Inc
KO:214320
|
0.061x |
|
Zevra Therapeutics Inc.
NASDAQ:ZVRA
|
0.035x |
|
Velesto Energy Bhd
KLSE:5243
|
0.016x |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
0.056x |
|
BTQ Technologies Corp.
NEO:BTQ
|
-0.343x |
|
Hainan RuiZe New Building Material Co Ltd
SHE:002596
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Veradigm Inc. (1998–2024)
The table below shows the annual cash flow conversion efficiency of Veradigm Inc. from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Veradigm Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.02 Billion | $115.56 Million | 0.114x | 0.00% |
| 2022-12-31 | $1.02 Billion | $115.56 Million | 0.114x | +312.03% |
| 2021-12-31 | $1.41 Billion | $-75.43 Million | -0.054x | +16.36% |
| 2020-12-31 | $1.67 Billion | $-106.72 Million | -0.064x | -277.95% |
| 2019-12-31 | $1.29 Billion | $46.25 Million | 0.036x | -16.23% |
| 2018-12-31 | $1.58 Billion | $67.90 Million | 0.043x | -75.53% |
| 2017-12-31 | $1.59 Billion | $279.42 Million | 0.176x | +8.39% |
| 2016-12-31 | $1.66 Billion | $269.00 Million | 0.162x | +8.62% |
| 2015-12-31 | $1.42 Billion | $211.58 Million | 0.149x | +85.01% |
| 2014-12-31 | $1.28 Billion | $103.50 Million | 0.081x | +31.16% |
| 2013-12-31 | $1.32 Billion | $80.99 Million | 0.061x | -64.56% |
| 2012-12-31 | $1.28 Billion | $222.67 Million | 0.173x | -4.74% |
| 2011-12-31 | $1.48 Billion | $268.75 Million | 0.182x | +80.01% |
| 2010-12-31 | $1.38 Billion | $139.90 Million | 0.101x | -49.39% |
| 2009-12-31 | $700.40 Million | $139.92 Million | 0.200x | +287.81% |
| 2008-12-31 | $700.37 Million | $36.08 Million | 0.052x | 0.00% |
| 2007-12-31 | $700.37 Million | $36.08 Million | 0.052x | -40.57% |
| 2006-12-31 | $316.25 Million | $27.41 Million | 0.087x | -48.32% |
| 2005-12-31 | $98.42 Million | $16.51 Million | 0.168x | +6.04% |
| 2004-12-31 | $78.69 Million | $12.45 Million | 0.158x | +153.41% |
| 2003-12-31 | $83.39 Million | $5.21 Million | 0.062x | +149.74% |
| 2002-12-31 | $85.82 Million | $-10.77 Million | -0.125x | +62.45% |
| 2001-12-31 | $98.63 Million | $-32.96 Million | -0.334x | -289.26% |
| 2000-12-31 | $290.98 Million | $-24.98 Million | -0.086x | +54.44% |
| 1999-12-31 | $67.40 Million | $-12.70 Million | -0.188x | +74.43% |
| 1998-12-31 | $5.70 Million | $-4.20 Million | -0.737x | -- |
About Veradigm Inc.
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle se… Read more